bluebird bio Inc (NAS:BLUE)
$ 0.6063 0.0323 (5.63%) Market Cap: 116.86 Mil Enterprise Value: 240.32 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 25/100

bluebird bio Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 18, 2020 / 02:05PM GMT
Release Date Price: $36.68 (+1.32%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

All right. Good morning. Good afternoon, everybody. Thanks for joining us at -- for the next company presenter at the Bank of America Global Healthcare Conference. I'm thrilled to be introducing our next company presenter, bluebird bio, a biotechnology company focused on gene and cell therapies. Just by way of background, I cover SMID-cap biotech at Bank of America. So I'm pleased to be introducing -- or moderating today's fireside chat with Chip Baird, CFO; and David Davidson, Chief Medical Officer.

So gentlemen, first off, thank you for joining us today.

David M. Davidson
bluebird bio, Inc. - Chief Medical Officer

Our pleasure, Jason.

William D. Baird
bluebird bio, Inc. - CFO

Yes. Thanks for having us.

Questions & Answers

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Yes, of course, of course. So I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot